Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Matinas Biopharma Holdings Inc’s current trading price is -97.21% away from its 52-week high, while its distance from the 52-week low is -68.42%. The stock’s price range during this period has varied between $1.90 and $21.50. The company, active in the Healthcare sector, saw a trading volume of around 1.85 million for the day, considerably higher average daily volume of 46540.0 observed over the last three months.
Matinas Biopharma Holdings Inc’s stock has seen a rocky market performance. The company’s stock achieved a 1-year high of $21.50 on 03/22/24, and the lowest price during that time was $1.90, recorded on 10/31/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
Matinas Biopharma Holdings Inc (MTNB) has experienced a quarterly decline of -92.61% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.01M and boasts a workforce of 32 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.8727, with a change in price of -7.4629. Similarly, Matinas Biopharma Holdings Inc recorded 51,643 in trading volume during the last 100 days, posting a change of -92.71%.
How MTNB’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for MTNB stands at 0.17. Similarly, the long-term debt-to-equity ratio is also 0.13.
MTNB Stock Stochastic Average
As of today, the raw stochastic average of Matinas Biopharma Holdings Inc over the last 50 days is at 0.30%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 0.53%. Further, the company’s Stochastic %K and %D values for the last 20 days were 5.81% and 12.38%, respectively.
MTNB Stock Price Performance Analysis
The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The index has shown a price loss of -94.45% this year. Over the last six months, there has been a stronger performance of -93.46%. The price of MTNB leaped by -80.45% during the last 30 days period. For the last 5-days stocks have slided -81.31%.
